Figure 2.
Fragment based drug design: The halogen-substituted indole element as starting point for the development of DYRK1A inhibitors with decreased molecular mass and lipophilicity.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.